Exchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
3.11% INR34.85
America/New_York / 8 mai 2024 @ 05:59
FUNDAMENTALS | |
---|---|
MarketCap: | 7 815.50 mill |
EPS: | 0.360 |
P/E: | 96.81 |
Earnings Date: | May 27, 2024 |
SharesOutstanding: | 224.26 mill |
Avg Daily Volume: | 1.354 mill |
RATING 2024-05-08 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 96.81 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 96.81 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
INR-2.10 (-106.02%) INR-36.95 |
Date: 2024-05-08 |
Expected Trading Range (DAY) |
---|
INR 32.85 - 36.85 ( +/- 5.74%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | INR34.85 (3.11% ) |
Volume | 0.874 mill |
Avg. Vol. | 1.354 mill |
% of Avg. Vol | 64.57 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.